JP6411523B2 - プリナブリン及びタキサンの組合せがん治療 - Google Patents

プリナブリン及びタキサンの組合せがん治療 Download PDF

Info

Publication number
JP6411523B2
JP6411523B2 JP2016547208A JP2016547208A JP6411523B2 JP 6411523 B2 JP6411523 B2 JP 6411523B2 JP 2016547208 A JP2016547208 A JP 2016547208A JP 2016547208 A JP2016547208 A JP 2016547208A JP 6411523 B2 JP6411523 B2 JP 6411523B2
Authority
JP
Japan
Prior art keywords
docetaxel
plinabulin
tumor
group
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016547208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536352A (ja
JP2016536352A5 (OSRAM
Inventor
ファン，ラン
Original Assignee
ビヨンドスプリング インコーポレイテッド
ビヨンドスプリング インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52812462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6411523(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ビヨンドスプリング インコーポレイテッド, ビヨンドスプリング インコーポレイテッド filed Critical ビヨンドスプリング インコーポレイテッド
Publication of JP2016536352A publication Critical patent/JP2016536352A/ja
Publication of JP2016536352A5 publication Critical patent/JP2016536352A5/ja
Application granted granted Critical
Publication of JP6411523B2 publication Critical patent/JP6411523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016547208A 2013-10-11 2013-10-11 プリナブリン及びタキサンの組合せがん治療 Active JP6411523B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/085075 WO2015051543A1 (en) 2013-10-11 2013-10-11 Cancer treatment with combination of plinabulin and taxane

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018179866A Division JP2018199726A (ja) 2018-09-26 2018-09-26 プリナブリン及びタキサンの組合せがん治療

Publications (3)

Publication Number Publication Date
JP2016536352A JP2016536352A (ja) 2016-11-24
JP2016536352A5 JP2016536352A5 (OSRAM) 2017-01-05
JP6411523B2 true JP6411523B2 (ja) 2018-10-24

Family

ID=52812462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016547208A Active JP6411523B2 (ja) 2013-10-11 2013-10-11 プリナブリン及びタキサンの組合せがん治療

Country Status (18)

Country Link
US (2) US10596169B2 (OSRAM)
EP (1) EP3076972B1 (OSRAM)
JP (1) JP6411523B2 (OSRAM)
KR (1) KR102225371B1 (OSRAM)
CN (1) CN105705148B (OSRAM)
AU (1) AU2013402794B2 (OSRAM)
BR (1) BR112016007946A2 (OSRAM)
CA (1) CA2926771C (OSRAM)
DK (1) DK3076972T3 (OSRAM)
ES (1) ES2902665T3 (OSRAM)
IL (1) IL244984B (OSRAM)
MX (1) MX384751B (OSRAM)
MY (1) MY185650A (OSRAM)
NZ (1) NZ719049A (OSRAM)
RU (1) RU2662298C2 (OSRAM)
SG (1) SG11201602637QA (OSRAM)
WO (1) WO2015051543A1 (OSRAM)
ZA (1) ZA201602380B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US10668063B2 (en) 2015-03-06 2020-06-02 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170117113A (ko) * 2015-02-12 2017-10-20 비욘드스프링 파마수티컬스, 인코포레이티드. 면역 관문 저해제와 조합한 플리나불린의 용도
CN109516981B (zh) * 2015-07-13 2019-10-22 大连万春布林医药有限公司 普那布林组合物
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20240091084A (ko) * 2016-06-06 2024-06-21 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증을 줄이는 조성물 및 방법
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019018880A2 (pt) * 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
CN109498627B (zh) * 2017-09-15 2021-06-04 深圳华大海洋科技有限公司 一种治疗肿瘤的药物组合物及其应用
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia
AU2019216305B2 (en) * 2018-02-01 2024-11-21 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent
CN108524442B (zh) * 2018-06-05 2022-01-28 深圳海王医药科技研究院有限公司 一种抗肿瘤药物的注射剂及其制备方法
JP2018199726A (ja) * 2018-09-26 2018-12-20 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療
CN113661253B (zh) * 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
CN110507653B (zh) * 2019-08-02 2022-12-02 北京赛而生物药业有限公司 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用
JP2022552011A (ja) * 2019-10-15 2022-12-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 鉄障害を処置するための方法及び組成物
JP2024513505A (ja) 2021-04-09 2024-03-25 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 腫瘍を治療するための組成物及び方法
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
MXPA05001217A (es) 2002-08-02 2005-05-16 Nereus Pharmaceuticals Inc Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CA2553630A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US10668063B2 (en) 2015-03-06 2020-06-02 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US11400086B2 (en) 2017-02-01 2022-08-02 Beyondspring Pharmaceuticals, Inc. Method of reducing chemotherapy-induced neutropenia

Also Published As

Publication number Publication date
IL244984A0 (en) 2016-05-31
EP3076972A1 (en) 2016-10-12
WO2015051543A1 (en) 2015-04-16
ZA201602380B (en) 2022-05-25
MY185650A (en) 2021-05-27
IL244984B (en) 2022-05-01
CA2926771C (en) 2022-07-05
MX2016004441A (es) 2016-10-28
KR20160078987A (ko) 2016-07-05
JP2016536352A (ja) 2016-11-24
DK3076972T3 (da) 2022-01-03
WO2015051543A8 (en) 2016-04-21
SG11201602637QA (en) 2016-05-30
MX384751B (es) 2025-03-14
AU2013402794B2 (en) 2020-02-27
EP3076972A4 (en) 2017-12-20
NZ719049A (en) 2020-06-26
BR112016007946A2 (pt) 2017-09-12
KR102225371B1 (ko) 2021-03-10
CN105705148A (zh) 2016-06-22
US20200281921A1 (en) 2020-09-10
EP3076972B1 (en) 2021-10-06
US10596169B2 (en) 2020-03-24
US20160250209A1 (en) 2016-09-01
CN105705148B (zh) 2021-03-23
RU2016112608A (ru) 2017-11-16
CA2926771A1 (en) 2015-04-16
ES2902665T3 (es) 2022-03-29
AU2013402794A1 (en) 2016-05-12
RU2662298C2 (ru) 2018-07-25

Similar Documents

Publication Publication Date Title
JP6411523B2 (ja) プリナブリン及びタキサンの組合せがん治療
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
WO2017004092A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2012500180A5 (OSRAM)
KR20080091866A (ko) Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를 포함하는 배합물
WO2014142220A1 (ja) 抗腫瘍剤
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
JP2022529295A (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
ES2984487T3 (es) Uso combinado de marizomib y bevacizumab para el tratamiento de cánceres del sistema nervioso central (SNC)
JP2018199726A (ja) プリナブリン及びタキサンの組合せがん治療
JP2021508699A (ja) トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用
HK1229712B (en) Cancer treatment with combination of plinabulin and taxane
WO2018133838A1 (zh) Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
US20230338347A1 (en) New Use of Inhibitors of the Notch Signalling Pathway
CN115779095A (zh) 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合
JP2019513767A (ja) マントル細胞リンパ腫の治療における使用のためのラムシルマブ及びアベマシクリブの組み合わせ療法
JP2025505381A (ja) フタラジノン誘導体を含む抗癌剤との併用投与用薬学的組成物
AU2022233742A1 (en) Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160613

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180620

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180926

R150 Certificate of patent or registration of utility model

Ref document number: 6411523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250